Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences with a $55 price target, citing its strong late-stage pipeline and solid cash position. Key catalysts include upcoming FDA decisions for bezuclastinib and IND submissions. The firm notes the company's runway into late 2028 reduces near-term financing risk. Piper Sandler also maintains a Buy rating with a $55 target.
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cogent Biosciences, with a price target of $55.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Robert Burns has given his Buy rating due to a combination of factors, including Cogent Biosciences’ strong late‑stage pipeline and solid financial position. He highlights the upcoming FDA decisions on bezuclastinib in GIST and non‑advanced systemic mastocytosis, along with additional IND submissions for other targeted oncology candidates, as key value‑creating catalysts over the next year.
Burns also underscores Cogent’s sizable cash balance and projected runway into late 2028, which supports ongoing development with limited near‑term financing risk. Using a DCF framework that applies high probabilities of approval across bezuclastinib’s lead indications, he arrives at an unchanged 12‑month price target of $55, while acknowledging typical biopharma risks such as clinical, regulatory, and commercialization uncertainties.
In another report released on August 17, Piper Sandler also maintained a Buy rating on the stock with a $55.00 price target.